Results 121 to 130 of about 8,209 (210)

Filgotinib Is an Effective and Safe Treatment Option for Difficult‐To‐Treat Ulcerative Colitis: Real‐World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Filgotinib is a preferential Janus kinase 1 (JAK‐1) inhibitor registered for the treatment of ulcerative colitis (UC). Real‐world effectiveness of filgotinib, especially for difficult‐to‐treat (DTT, failure of ≥ 2 prior advanced therapies) patients, has been scarcely reported.
M. R. Naber, A.E van der Meulen, P. W. Voorneveld, S. H. C. Veltkamp, A.A. van Bodegraven, A. Bodelier, Z. Mujagic, M. Pierik, L. M. M. Verleye, M. Duijvestein, D. G. Bouwknegt, M. C. Visschedijk, N. Srivastava, R. L. West, B. Oldenburg, M. Löwenberg, F.D.M. van Schaik, On behalf of the Dutch ICC Registry   +17 more
wiley   +1 more source

Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis

Clinical and Translational Science
Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto‐immune conditions, such as axial spondyloarthritis, an inflammatory rheumatic disease that includes ankylosing spondylitis (AS) and non ...
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In‐Ho Song, Peter Wung, Wei Liu, Mohamed‐Eslam F. Mohamed   +6 more
doaj   +1 more source

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions

Allergy, Volume 81, Issue 2, Page 326-344, February 2026.
ABSTRACT Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment ...
Marjolein S. de Bruin‐Weller, Celeste M. Boesjes, Roselie A. Achten, Lisa A. Beck, Alan D. Irvine, Christian Vestergaard, Marlies de Graaf, Femke van Wijk, Daphne S. Bakker, Stephan Weidinger   +9 more
wiley   +1 more source

Clinical and Molecular Effect of the Anti–IL‐18 Antibody Aletekitug in Adults With Atopic Dermatitis

Allergy, Volume 81, Issue 2, Page 539-551, February 2026.
At Week 12, aletekitug was associated with a −68.3% percentage change from baseline in EASI score. Aletekitug improved the transcriptional profile of lesional skin towards that of non‐lesional skin at Week 4 and Week 12. Aletekitug was well‐tolerated; no serious adverse event or death occurred, and no patient withdrew due to an adverse event.
Joanne Ellis, Léa Fortunato, Hannah Wajdner, Ester Del Duca, Joanna Barnard, Joanna C. Betts, Swaroop Bose, John Browning, Núria Buil‐Bruna, Scott Van Buren, Eden David, Scott Dinehart, Puneet Dhawan, Yeriel Estrada, Parima Ghafoori, Kiranmai Gumireddy, Zhenghong Li, Wei Jing Loo, Fiona Lovegrove, Jenny Lowe, Lawrence Charles Parish, Will Powley, Naveen Prasad, Joel Correa Da Rosa, Marieta Ruseva, Neda Shokrian, Farhat Syed, Chun‐Hang Tang, Gabriel K. Wong, John B. Kelly, Nicolas Wisniacki, Iain Uings, Emma Guttman‐Yassky   +32 more
wiley   +1 more source

Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. [PDF]

BACKGROUND AND OBJECTIVE: Upadacitinib is indicated for diseases affecting persons of childbearing potential including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, Crohns disease, and ulcerative colitis; however,
Ali, Mira, Bhutani-Jacques, Tina, Chambers, Christina, Clowse, Megan, Gensler, Lianne, Kimball, Alexa, Lacerda, Ana, Levy, Gweneth, Long, Millie, Mahadevan, Uma, Palac, Hannah, Scialli, Anthony, Wegrzyn, Lani   +12 more
core   +1 more source

Infections in Patients with Atopic Dermatitis and the Infuence of Treatment [PDF]

Atopic dermatitis (AD) is a T helper 2-mediated chronic infammatory skin disease that afects children and adults. Patients with AD are prone to recurrent infections of the skin and other organs, which can severely worsen the disease course. This review
Maddalena Napolitano, · Caterina Foti, · Elena Nicoli, · Giampiero Girolomoni, · Maria Concetta Fargnoli, · Maria Esposito, · Paolo Matruglio, · Paolo Romita   +7 more
core   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Off-label use of upadacitinib in dermatology: a review

Journal of Dermatological Treatment
Objectives Upadacitinib, a selective JAK1 inhibitor, is approved for the treatment of atopic dermatitis but is increasingly used off-label in dermatology.
Hongtao Yu, Junkai Zhu, Xiaoli Ni, Kaiyu Yu, Zhen Mu   +4 more
doaj   +1 more source

Can in vitro/in silico tools improve colonic concentration estimations for oral extended-release formulations? A case study with upadacitinib [PDF]

Upadacitinib, classified as a highly soluble drug, is commercially marketed as RINVOQ®, a modified-release formulation incorporating hydroxypropyl methylcellulose as a matrix system to target extended release throughout the gastrointestinal (GI) tract ...
Alvarenga de Oliveira, M, Basit, AW, Favaron, A, Hens, B, McAllister, M, Montanha, M, Moustafa, S, Orlu, M, Tomaszewska, I   +8 more
core  

Tofacitinib‐Induced Weight Gain in Context: comment on the article by Wollenhaupt et al.

ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Andriko Palmowski, Frank Buttgereit, David Simon, Arnd Kleyer, Norman Michael Drzeniek   +4 more
wiley   +1 more source